A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

This study is testing a new experimental medicine, VVD-159642, to see if it can safely stop or shrink advanced solid tumors. It matters because researchers are looking for new ways to treat cancers that have specific genetic changes by blocking the signals that help them grow.

This trial is for adults with advanced cancers—like lung, pancreatic, or colorectal—that have spread or cannot be removed by surgery. You must have certain genetic markers in your tumor, be able to perform daily tasks, and have healthy organ function.

You will receive either the new medicine alone or combined with other approved treatments to see how your body reacts and how the tumor responds. Throughout the study, you will have regular check-ups to monitor your safety and the effectiveness of the treatment.

This study is currently recruiting patients at locations in Grand Rapids, Michigan, and in Austin and Irving, Texas. Because it is a Phase 1 study, the goal is primarily to find the right dose and ensure the medicine is safe for people to take.